Within the clinical range (from ~15% to ~55%) where treat no one and treat everyone were not the optimal options, the optimal approaches to decide on OCA prescription were by using total bilirubin values and MELD, as reflected by the higher net benefit curves compared to those observed for albumin, Child‐Pugh score and history of ascites. This evidence concerns the gene ALB and Ascites.